FMO5 and diabetes mellitus: In a short-term model of diabetes-induced endothelial dysfunction, treatment with the IL-1 receptor antagonist, anakinra, restored endothelial-dependent relaxation, with concomitant reduction of vascular NADPH oxidase and NF-κB activation (Vallejo et al., 2014).